Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema.
Cardillo
J A
JA
Souza-Filho
A A
AA
Oliveira
A G
AG
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D048909:Diabetes Complications / Q000188:drug therapy*; D004341:Drug Evaluation; D006016:Glycolates / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007267:Injections; D019344:Lactic Acid; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008863:Microspheres; D010865:Pilot Projects; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D006016:Glycolates; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D014222:Triamcinolone Acetonide